Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study

Journal of Nephrology

Volumn 28, Issue 1, 2015, Pages 105-113

  Lee, Chien Te ^a,b   Wu, I Wen ^a,b   Chiang, Shou Shan ^c   Peng, Yu Sen ^d   Shu, Kuo Hsiung ^e   Wu, Ming Ju ^e   Wu, Mai Szu ^f,g  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Ferric citrate; Hemodialysis; Iron metabolism; Phosphate

Indexed keywords

BICARBONATE; FERRIC CITRATE; HEMOGLOBIN; PLACEBO; TRANSFERRIN; VITAMIN D; CHELATING AGENT; FERRIC ION; FERRITIN; PHOSPHORUS;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CONSTIPATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; END STAGE RENAL DISEASE; FECES INCONTINENCE; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; ADVERSE EFFECTS; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; KIDNEY FAILURE, CHRONIC; METABOLISM; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY;

ADMINISTRATION, ORAL; ADULT; AGED; CHELATING AGENTS; DOUBLE-BLIND METHOD; FEMALE; FERRIC COMPOUNDS; FERRITINS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHORUS; RENAL DIALYSIS; TRANSFERRIN;

EID: 84922574601     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0108-6     Document Type: Article

References (22)

1. Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128
2. US Renal Data System (2013) USRDS 2013 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda
3. Thodis ED, Oreopoulos DG (2011) Home dialysis first: a new paradigm for new ESRD patients. J Nephrol 24:398–404
4. Coladonato JA (2005) Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 16(Suppl 2):S107–S114
5. Qunibi WY (2004) Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int Suppl 90:S8–S12
6. Kusano E (2011) Mechanism by which chronic kidney disease causes cardiovascular disease and the measures to manage this phenomenon. Clin Exp Nephrol 15:627–633
7. Miller LM, Sood MM, Sood AR et al (2010) Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients. Int Urol Nephrol 42:1007–1014
8. Qunibi W, Kalantar-Zadeh K (2011) Target levels for serum phosphorus and parathyroid hormone. Semin Dial 24:29–33
9. Gutiérrez OM, Wolf M (2010) Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies. Semin Dial 23:401–406
10. Tonelli M, Pannu N, Manns B (2010) Oral phosphate binders in patients with kidney failure. N Engl J Med 362:1312–1324
11. Hutchison AJ, Smith CP, Brenchley PE (2011) Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 7:578–589
12. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH (2002) An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant 17:265–270
13. Dwyer JP, Sika M, Schulman G et al (2013) Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 61:759–766
14. Sinsakul M, Sika M, Koury M et al (2012) The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 121:c25–c29
15. Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y (2012) Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 36:478–487
16. Yokoyama K, Akiba T, Fukagawa M et al (2014) A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant 29(5):1053–1060
17. Panion & BF Biotech, Inc. (2006) A randomized, double-blind, placebo-controlled, dose-ranging study of the effects of ferric citrate on serum phosphate in patients with end stage renal disease (ESRD). Panion & BF Biotech, Inc., Report No. PBB00101
18. Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. J Am Soc Nephrol 23:1631–1634
19. Calvo MS, Uribarri J (2013) Contributions to total phosphorus intake: all sources considered. Semin Dial 26:54–61
20. Hsu CH, Patel SR, Young EW (1999) New phosphate binding agents: ferric compounds. J Am Soc Nephrol 10:1274–1280
21. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO Clinical Practice Guideline for anemia in chronic kidney disease. Kidney Int 2(Suppl):279–335
22. Fishbane S (2008) Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines. Semin Dial 21:217–220